Pharma

sponsor

Topics in Pharma

Conferences/Meetings

Drug/Product Approvals

Execs on the Move

Financial Reports

M&A/Partnerships

Marketing/Media/ROI

Medical Devices/Products

Physician/Patient Trends

Regulatory Issues

Research & Development

Become a Member Today!
Register

Most Viewed Abstracts

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Cell Therapeutics, 08/11/09

Cell Therapeutics, Inc. reported recent achievements and financial results for the second quarter and six months ended June 2009.

<< Previous
OPAXIO Combined with Alimta Well Tolerated in Dose-Ranging Study...

Next >>
MedImmune Advances Three Oncology Programs Into the Clinic

Today in Drug/Product Approvals...keeping you current

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

See all of Drug/Product Approvals

Today in Financial Reports...keeping you current

HP to Acquire Networking Firm 3Com
HealthDataManagement, 11/20/09

Protox Reports 2009 Third Quarter Results
Protox Therapeutics , 11/18/09

King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
King Pharmaceuticals, 11/16/09

See all of Financial Reports

Article Search

Sponsor

Send this Summary to a Colleague